Actinium Pharmaceuticals, Inc
ATNMActinium Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing targeted cancer therapies using its proprietary Antibody-Radionuclide Conjugate (ARC) platform. The company specializes in creating treatments for hematologic malignancies and other cancers, leveraging its expertise in radiolabeled antibody technology to deliver targeted radiation directly to cancer cells.
Company News
The targeted alpha therapy market is experiencing rapid growth driven by advancements in alpha emitters like Actinium-225, Astatine-211, and Lead-212 across clinical stages. Over 30 drugs are in clinical trials, with promising results in treating metastatic and drug-resistant cancers including prostate cancer and hepatocellular carcinoma. Major p...
A new market research report reveals targeted alpha therapies (TAT) for cancer treatment are projected to grow from $199.6 million in 2024 to $1.1 billion by 2030, with a 44% CAGR, driven by precision medicine and unmet oncology treatment needs.
Rosen Law Firm is encouraging investors in Actinium Pharmaceuticals, Inc. (ATNM) who have lost more than $100,000 to seek legal counsel before the May 27 deadline for a securities class action lawsuit. The lawsuit alleges that the company made false and misleading statements about the likelihood of its Iomab-B drug candidate being approved by the...
Rosen Law Firm is encouraging investors of Actinium Pharmaceuticals, Inc. (ATNM) who have lost more than $100,000 to secure legal counsel before the May 27, 2025 deadline for a securities class action lawsuit.
A class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. (ATNM) for allegedly making materially false and misleading statements about the likelihood of FDA approval for its drug Iomab-B.
